Apellis制药公司错过了2025年Q4收入估计数,报告了损失,收入下降,尽管先前是Q3打拍。 Apellis Pharmaceuticals missed Q4 2025 earnings estimates, reported a loss, and saw revenue drop, despite prior Q3 beat.

Apellis制药公司报告,2025年第四季度每股损失0.47美元,估计损失8美元,收入逐年下降1 262万美元。 Apellis Pharmaceuticals reported a fourth-quarter 2025 loss of $0.47 per share, missing estimates by $0.08, and saw revenue drop $12.62 million year-over-year. 该公司此前在2025年第三季度已超出预期，推动股价上涨。 The company had previously beat expectations in Q3 2025, driving a stock increase. 分析员维持“等待”共识,平均价格目标是33.00美元,1月22日注意到内幕销售情况。 Analysts maintain a "Hold" consensus with a $33.00 average price target, while insider sales were noted on January 22. 股票交易的市场上限为28.4亿美元,12个月范围在16.10美元至30.48美元之间。 The stock trades with a market cap of $2.84 billion and a 12-month range of $16.10 to $30.48.